Setmelanotide (Imcivree): MC4R Agonist for Rare Genetic Obesity — Research Overview

Setmelanotide (brand name Imcivree) is a cyclic heptapeptide melanocortin-4 receptor (MC4R) agonist approved by the FDA in November 2020 for chronic weight management in patients with obesity caused by pathogenic variants in the POMC, PCSK1, or LEPR genes — and subsequently for Bardet-Biedl syndrome (BBS) in June 2022. These genetic conditions impair the hypothalamic melanocortin pathway, causing severe, early-onset hyperphagia and obesity that is largely unresponsive to conventional weight-loss interventions. Setmelanotide is the first pharmacotherapy specifically designed to restore this disrupted pathway and represents a precision medicine breakthrough for a group of patients who had previously lacked effective treatment options.

What Is Setmelanotide?

Setmelanotide is a synthetic cyclic octapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), a neuropeptide derived from the proopiomelanocortin (POMC) precursor. Native α-MSH is the primary endogenous agonist at MC4R, a G-protein-coupled receptor in the hypothalamus that plays a central role in regulating energy homeostasis, satiety, and body weight. Setmelanotide was developed by Rhythm Pharmaceuticals and engineered to have MC4R selectivity with reduced activity at MC1R (which mediates skin pigmentation) and other melanocortin receptor subtypes, though MC1R activity is not fully absent, explaining the skin hyperpigmentation side effect observed in clinical trials.

The conditions Imcivree treats involve specific disruptions in the hypothalamic melanocortin signaling cascade. POMC deficiency prevents production of α-MSH, leaving MC4R unstimulated. PCSK1 deficiency impairs processing of POMC into α-MSH. LEPR deficiency blocks leptin signaling upstream of POMC neurons, reducing α-MSH output. Bardet-Biedl syndrome involves dysfunction of primary cilia in hypothalamic neurons, impairing MC4R pathway signaling. In each case, the result is profound hyperphagia and obesity beginning in early childhood.

Mechanism of Action

Setmelanotide acts as an agonist at MC4R in the paraventricular nucleus (PVN) of the hypothalamus and potentially other hypothalamic and brainstem regions where MC4R is expressed. Binding to MC4R activates Gs-coupled intracellular signaling, increasing cAMP and activating downstream anorectic pathways. This produces reduced food intake (decreased hyperphagia), increased satiety signaling, and — to a lesser degree — increased energy expenditure.

The critical distinction between setmelanotide and general-purpose weight-loss agents is pathway specificity: setmelanotide bypasses the upstream signaling defect (absent α-MSH or impaired leptin signaling) and directly activates MC4R. In patients without a defect in this pathway, the effect on weight would be expected to be more modest and unpredictable. The FDA approval is therefore confined to genetically confirmed pathway deficiencies. Patients with variant-of-uncertain-significance (VUS) in POMC, PCSK1, or LEPR may also qualify under the label, which specifies pathogenic, likely pathogenic, or VUS variants confirmed by genetic testing.

What the Research Shows

The pivotal evidence supporting the initial FDA approval came from two open-label Phase 3 trials published by Clément et al. in the New England Journal of Medicine in 2020 (PMID 33308459). Study 1 enrolled 10 patients with POMC or PCSK1 deficiency obesity; Study 2 enrolled 11 patients with LEPR deficiency obesity. Both studies used setmelanotide 3 mg subcutaneously once daily (with optional titration up to 3 mg) over approximately one year. The primary endpoint was achievement of ≥10% body weight reduction from baseline at 52 weeks.

In the POMC/PCSK1 cohort, 80% of patients met the primary endpoint. In the LEPR cohort, 45% met the endpoint. Hunger scores measured by visual analogue scale improved significantly in both groups. Weight loss was dramatic in many patients, with some achieving >25% body weight reduction. These results were considered clinically compelling given the severity and chronicity of obesity in these populations and the historical absence of effective pharmacotherapy.

The Bardet-Biedl syndrome evidence base rests on a Phase 3 trial published by Haqq et al. in The Lancet Diabetes & Endocrinology in 2022 (PMID 36356613). This randomized, double-blind, placebo-controlled trial enrolled 38 patients (32 with BBS, 6 with Alström syndrome) and used a 14-week blinded period followed by a 52-week open-label extension. In the BBS cohort, 32.3% of patients achieved ≥10% body weight reduction at 52 weeks on setmelanotide. Significant reductions in hunger scores were also documented. These results supported the 2022 label expansion to include BBS.

Long-term data from a 4-year follow-up in POMC and LEPR cohorts (presented at ECE 2024) showed sustained weight maintenance. Common adverse events across trials were skin hyperpigmentation (related to MC1R agonism), injection site reactions, nausea, and headache. Cases of suicidal ideation were reported in the BBS trial but were not considered drug-related. The FDA label requires monitoring for depression and suicidal ideation.

Pharmacokinetics

Setmelanotide is administered as a once-daily subcutaneous injection. Following subcutaneous dosing, the absolute bioavailability is approximately 100%. Peak plasma concentrations (Tmax) occur at approximately 8 hours after injection. The mean terminal half-life is approximately 11 hours, supporting once-daily dosing. Volume of distribution is approximately 19.4 L, indicating moderate tissue distribution.

Setmelanotide is primarily eliminated via proteolytic degradation and renal clearance. The FDA label specifies dose adjustment for patients with moderate or severe renal impairment (eGFR < 30 mL/min/1.73m²): the label states setmelanotide has not been studied in patients with end-stage renal disease or on dialysis, and its use is not recommended in those populations. No clinically significant drug-drug interactions have been identified.

Approved Indications and Clinical Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Setmelanotide (Imcivree) is FDA-approved for chronic weight management in adults and pediatric patients 6 years of age and older with obesity due to: (1) POMC, PCSK1, or LEPR deficiency confirmed by pathogenic, likely pathogenic, or variant-of-uncertain-significance genetic variants; (2) Bardet-Biedl syndrome. The FDA label specifies the following dosing regimen: initiate at 0.5 mg SC once daily for 2 weeks, then increase to 1 mg once daily for 2 weeks, then increase to 2 mg once daily. A maintenance dose of up to 3 mg once daily may be used. For patients aged 6–11 years, the starting and titration doses are lower (0.5 mg initial; 1 mg maintenance target; maximum 3 mg).

The label specifies that if a patient does not lose at least 5% of body weight after 12–16 weeks at the maximum tolerated dose, therapy should be discontinued. All prescribing decisions rest with the treating clinician. Setmelanotide is not approved for common (polygenic) obesity.

Storage and Handling

Imcivree (setmelanotide) injection is supplied as a 10 mg/mL solution in a multi-dose vial. The FDA label specifies refrigerated storage at 2–8°C (36–46°F) before opening. After opening, the vial may be stored refrigerated or at room temperature up to 30°C (86°F) for up to 30 days. Vials should not be frozen. Each vial is supplied with dosing syringes; solutions should be inspected for particulate matter and discoloration prior to administration.

What Setmelanotide Is NOT

Setmelanotide is sometimes discussed alongside GLP-1 agonists (semaglutide, tirzepatide) as a weight-loss agent, but the two drug classes are mechanistically and clinically distinct. GLP-1 agonists act on the incretin axis and are approved for common obesity and type 2 diabetes across broad populations. Setmelanotide acts specifically on the hypothalamic MC4R pathway and is approved exclusively for rare genetic obesity syndromes with confirmed MC4R pathway disruption.

Setmelanotide should not be confused with melanotan II (MT-II) or PT-141 (bremelanotide), which are non-selective melanocortin receptor agonists used in research settings for sexual dysfunction and tanning. MT-II binds non-selectively across MC1R, MC3R, MC4R, and MC5R. Setmelanotide has a more selective MC4R profile and is developed as a prescription therapeutic, not a research peptide. It should also not be confused with alpha-MSH itself, which is not available as a pharmaceutical product.

References

1. Clément K, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551–555. [Phase 2 data]

2. Clément K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–970. PMID 33308459.

3. Haqq AM, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(12):859–868. PMID 36356613.

4. U.S. FDA. Imcivree (setmelanotide) Prescribing Information. NDA 213793. Updated 2022.